ITCI News and Press, Intra-Cellular Therapies Inc. From 11/03/22

Intra-Cellular Therapies ( NASDAQ: ITCI ) stock rose ~11% on Thursday after the company's Q3 results beat estimates. Net loss narrowed to -$53.51, compared to -$76.91M in Q3 2021. Net product sales of bipolar depression therapy Caplyta increased +232.6...

Intra-Cellular Therapies press release ( NASDAQ: ITCI ): Q3 GAAP EPS of -$0.57 beats by $0.25 . Revenue of $71.9M (+223.7% Y/Y) beats by $5.9M . Cash, cash equivalents, restricted cash and investment securities totaled $630.5 million at September 30, 2022, comp...

CAPLYTA net product revenues for the third quarter 2022 were $71.9 million, compared to $21.6 million for the same period in 2021, representing a 233% increase over the same period in 2021 and a 30% increase over the second quarter 2022 Third quarter 2022 CAPLYTA total pres...

Intra-Cellular Therapies ( NASDAQ: ITCI ) is scheduled to announce Q3 earnings results on Thursday, November 3rd, before market open. The consensus EPS Estimate is -$0.84 (+11.6% Y/Y) and the consensus Revenue Estimate is $66M (+197.2% Y/Y). Over the last 1 year, ITCI ...

Summary Having suffered through a sharp decline in earnings multiples, small cap growth stocks held up well in a volatile quarter marked by a sharp upward ratcheting of interest rates. The Strategy underperformed its benchmark, primarily due to weakness among health care holdings ...

NEW YORK, Oct. 27, 2022 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it will host a conference call and li...

Summary Today, we circle back on mid-cap biopharma name Intra-Cellular Therapies, Inc. for the first time since 2020. Intra-Cellular Therapies' flagship product CAPLYTA (lumateperone) has significant potential across multiple indications including to treat bipolar disorder and sch...

Summary For over a year, Axsome Therapeutics suffered substantial share price depreciation due to the uncertain fate of its lead medicine (AXS05). Like the cream that always rises to the top, AXS05 recently gained FDA approval for major depressive disorder which catapulted share p...

Goldman Sachs downgraded commercial-stage biopharma Intra-Cellular Therapies, Inc. ( NASDAQ: ITCI ) to Neutral from Buy, noting the market dynamics for its only product Caplyta, a treatment indicated in the U.S. for schizophrenia and bipolar depression. The analysts note t...

Intra-Cellular Therapies, Inc. (ITCI) Q2 2022 Earnings Conference Call August 09, 2022, 08:30 AM ET Company Participants Juan Sanchez - Vice President, Corporate Communications and Investor Relations Sharon Mates - Chairman and Chief Executive Officer Mark Neuman...